Precigen, Inc.

22 patents currently held · Updated Nov 14, 2026

19 more in force are now held by other companies

Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Previously recorded as Intrexon Corporation (to 2020)

Ending by 2030

Jun 2037

Next term end

When these terms end

5 yrs10 yrs20 yrs

Held patents by the year their term ends

20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.

1 fee due Jan 4, 2027
The maintenance fee for Modulating Expression of Polypeptides via New Gene Switch Expression Systems (US 11,692,194) comes due Jan 4, 2027. Unpaid by Jul 6, 2027, it lapses early.
2 fees due Apr 3 to 17, 2027 · next Apr 3
1 fee due Oct 2, 2027
The maintenance fee for Modulating Expression of Polypeptides via New Gene Switch Expression Systems (US 11,946,054) comes due Oct 2, 2027. Unpaid by Apr 3, 2028, it lapses early.
1 fee due Nov 7, 2027
The maintenance fee for MUC16 Specific Chimeric Antigen Receptors and Uses Thereof (US 11,976,134) comes due Nov 7, 2027. Unpaid by May 8, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

2 of the patents on this record were granted since Aug 16, 2026

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.

Patent	Title	Status	Expires	Confidence
US 12,559,536	CD33 Specific Chimeric Antigen Receptors In force Term ends Jun 7, 2037 · High confidence	In force	Term ends Jun 7, 2037	High confidence
US 11,692,194	Modulating Expression of Polypeptides via New Gene Switch Expression Systems In force Term ends Jan 10, 2038 · High confidence	In force	Term ends Jan 10, 2038	High confidence
US 11,118,168	Expression of Novel Cell Tags In force Term ends Jun 6, 2038 · High confidence	In force	Term ends Jun 6, 2038	High confidence
US 11,116,852	Frataxin Expression Constructs In force Term ends Jul 27, 2038 · High confidence	In force	Term ends Jul 27, 2038	High confidence
US 11,608,362	Hepatitis B Vaccines and Uses of the Same In force Term ends Mar 6, 2039 · High confidence	In force	Term ends Mar 6, 2039	High confidence
US 12,234,261	Hepatitis B Vaccines and Uses of the Same In force Term ends Mar 6, 2039 · High confidence	In force	Term ends Mar 6, 2039	High confidence
US 12,180,517	Expression of Novel Cell Tags In force Term ends May 14, 2039 · High confidence	In force	Term ends May 14, 2039	High confidence
US 11,319,380	MUC16 Specific Chimeric Antigen Receptors and Uses Thereof In force Term ends Jun 4, 2039 · High confidence	In force	Term ends Jun 4, 2039	High confidence
US 11,976,134	MUC16 Specific Chimeric Antigen Receptors and Uses Thereof In force Ends no later than Jun 4, 2039 · Medium confidence	In force	Ends no later than Jun 4, 2039	Medium confidence
US 11,981,746	MUC16 Specific Chimeric Antigen Receptors and Uses Thereof In force Term ends Jun 4, 2039 · High confidence	In force	Term ends Jun 4, 2039	High confidence

10 of 22 patents shown.

Pro members see all 22.

Pro members: see all 22 patents

Also on record, not counted in the 22: 19 patents in force now held by others · 1 lapsed for an unpaid fee. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built

Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Export every term end as CSV · Pro

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

11 pending · 1 abandoned · 4 no status recorded

List them